The C-type natriuretic peptide analogue vosoritide significantly increases the growth rate of children with achondroplasia, indicate the results of a randomised, double-blind phase 3 study published in The Lancet.
Factors including age at diagnosis and the specific disease influence the likelihood of children with chronic endocrine conditions being lost to follow-up, show French study findings.
Professor Ravi Savarirayan talks through the recently published results in The New England Journal of Medicine for the C-type natriuretic peptide analogue vosoritide in children with achondroplasia.
Daily treatment with subcutaneous vosoritide leads to a sustained increase in annualised growth velocity, with generally mild side effects, in children with achondroplasia, show data published in The New England Journal of Medicine.
Burosumab treatment improves rickets and prevents decline in growth in young children with X-linked hypophosphataemia, show the findings of an open-label phase II study.
Burosumab treatment improves rickets and prevents decline in growth in young children with X-linked hypophosphataemia, show the findings of an open-label phase II study.
Researchers report sustained improvements in skeletal mineralisation, along with other benefits including improved growth and respiratory function, in children with life-threatening perinatal or infantile hypophosphatasia during 7 years of treatment with asfotase alfa.
Higher doses of vitamin D3 than currently recommended may be needed to achieve vitamin D sufficiency in schoolchildren living at northern latitudes, show the results of a randomised trial.
Findings from a large study indicate that 25-hydroxyvitamin D levels during foetal life are not linked to childhood bone health independently of childhood vitamin D exposure.
A study details the clinical characteristics of patients who have autosomal dominant short stature caused by heterozygous mutations in the aggrecan gene.